ArticleJournal of global infectious diseases
Extended-Spectrum Beta-lactamase Producers: Detection for the Diagnostic Laboratory.
Article in Journal of global infectious diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Antimicrobial resistance profile and molecular analysis of virulence among Escherichia coli isolated from pregnant women with asymptomatic bacteriuria in Gorgan, Iran.BMC pregnancy and childbirth · 2026Article
- Analysis of Clinical Gram-Negative Carbapenem Resistant Acinetobacter baumannii and Klebsiella pneumoniae Isolates from Wounds of Patients at a Hospital Reveals Complex Resistome and the First Report of blaCurrent microbiology · 2025Article
- Phenotypic, Targeted Genotypic, and Antimicrobial Susceptibility Profiling of Extended-Spectrum β-Lactamase Production and Exclusive blaJournal of clinical laboratory analysis · 2025Article
- Resistance inAntibiotics (Basel, Switzerland) · 2023Review
- Article
- Predominance of genetically diverse ESBL Escherichia coli identified in resistance mapping of Vembanad Lake, the largest fresh-cum-brackishwater lake of India.Environmental science and pollution research international · 2021Article
- Prolonged carriage of ESBL-producing enterobacterales and potential cross-transmission among residents in geriatric long-term care facilities.Scientific reports · 2021Article
- Prevalence of Antibiotic Resistance of ESKAPE Pathogens Over Five Years in an Infectious Diseases Hospital from South-East of Romania.Infection and drug resistance · 2021Article
- Distribution of Class B and Class A β-Lactamases in Clinical Strains ofInfection and drug resistance · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDiscovered in 1983, Extended spectrum beta-lactamase (ESBL) producers are still the leading cause of infections in India. Its prompt detection is crucial to the clinical management. The Clinical Laboratory Standards Institute (CLSI) recommends phenotypic screening and confirmatory tests to identify the ESBL producer making it cost and time consuming for the diagnostic laboratory. We compare here the screening and confirmatory tests offering a solution to the CLSI recommendation.
methodsNosocomial isolates RESULTS AND
conclusionsPhenotypic screening disk diffusion test versus the confirmatory agar dilution MIC tests with cefotaxime and ceftazidime correlated well with the final ESBL status (kappa 0.852 and 0.905
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.